AI-driven pilot platforms and computational pharmaceutics: accelerating innovation in small molecule drug development under industry 4.0 and 5.0 paradigms

In the era of artificial intelligence (AI) and Industry 4.0, pilot-scale platforms for small molecule chemical drugs are undergoing a transformative digital evolution. These platforms serve as a critical link between early-stage laboratory research and full-scale pharmaceutical manufacturing, ensuring process feasibility, scalability, and regulatory compliance. This review offers a comprehensive and forward-looking analysis of the structure, function, and strategic importance of pilot-scale systems within the modern pharmaceutical landscape. Focusing on the integration of AI and intelligent automation, the study highlights innovations such as AI-driven process optimization, predictive maintenance, data integration, digital twin technologies, and continuous manufacturing. These technologies are reshaping conventional production paradigms by enhancing efficiency, improving quality control, and reducing environmental impact. The convergence of computational pharmaceutics and green chemistry is also examined as a key driver of sustainable and intelligent drug development. Moreover, the review addresses the industry's transition toward Industry 5.0, characterized by human-machine collaboration, data-centric innovation, and an emphasis on sustainability. Persistent challenges such as equipment standardization gaps, data-sharing limitations, and outdated infrastructure are critically discussed. Drawing from industrial case studies, academic research, and best practices, this paper explores both the opportunities and constraints associated with AI-enabled pilot platforms. Ultimately, the review aims to inform future strategies in digital pharmaceutical manufacturing by underscoring the importance of technological innovation, regulatory alignment, and collaborative ecosystems in advancing the development, efficiency, and sustainability of small molecule drug production.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-03-04
DOI
https://doi.org/10.3389/fphar.2026.1681040
Primary Topic
Machine Learning in Materials Science
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

AI-driven pilot platforms and computational pharmaceutics: accelerating innovation in small molecule drug development under industry 4.0 and 5.0 paradigms

Ihab Elshoura, Lianyi He, Dingying Liu, Yuanzhe Cai et al.
Frontiers in Pharmacology
Machine Learning in Materials Science
article

AI-driven pilot platforms and computational pharmaceutics: accelerating innovation in small molecule drug development under industry 4.0 and 5.0 paradigms

Ihab Elshoura, Lianyi He, Dingying Liu, Yuanzhe Cai, Zaid Chachar, Yuhan Yang, Chenggong Zhong, Meiqi Chen, Sadaruddin Chachar, Kaixin Luo, Shahla Karim Baloch, Jun Xiong, Feijuan Huang
article en

Abstract

In the era of artificial intelligence (AI) and Industry 4.0, pilot-scale platforms for small molecule chemical drugs are undergoing a transformative digital evolution. These platforms serve as a critical link between early-stage laboratory research and full-scale pharmaceutical manufacturing, ensuring process feasibility, scalability, and regulatory compliance. This review offers a comprehensive and forward-looking analysis of the structure, function, and strategic importance of pilot-scale systems within the modern pharmaceutical landscape. Focusing on the integration of AI and intelligent automation, the study highlights innovations such as AI-driven process optimization, predictive maintenance, data integration, digital twin technologies, and continuous manufacturing. These technologies are reshaping conventional production paradigms by enhancing efficiency, improving quality control, and reducing environmental impact. The convergence of computational pharmaceutics and green chemistry is also examined as a key driver of sustainable and intelligent drug development. Moreover, the review addresses the industry's transition toward Industry 5.0, characterized by human-machine collaboration, data-centric innovation, and an emphasis on sustainability. Persistent challenges such as equipment standardization gaps, data-sharing limitations, and outdated infrastructure are critically discussed. Drawing from industrial case studies, academic research, and best practices, this paper explores both the opportunities and constraints associated with AI-enabled pilot platforms. Ultimately, the review aims to inform future strategies in digital pharmaceutical manufacturing by underscoring the importance of technological innovation, regulatory alignment, and collaborative ecosystems in advancing the development, efficiency, and sustainability of small molecule drug production.

Frontiers in PharmacologyVol. 17
Chinese University of Hong Kong, Shenzhen (CN), The Medical Device (United Kingdom) (GB), Shenzhen Technology University (CN), Shenzhen Second People's Hospital (CN), Sindh Agriculture University (PK), Nanjing University (CN)
Industry, innovation and infrastructure
Openalex Percentile: Top 36%
Machine Learning in Materials Science
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.